A New Member Joins the Science Sub-Committee of Great Bay Bio’s 3D Advisory Board

Created on:2019-08-27 10:45


August 27th,2019Press Release


A New Member Joins the Science Sub-Committee of Great Bay Bio’s 3D Advisory Board


[August 27, 2019 - Hong Kong] Great Bay Bio, a leading AI biotechnology company dedicated to big data-driven CMC (Chemistry Manufacturing and Controls) and biologics R&D, welcomes a new key member, Dr. Mark McHale to the Science Sub-Committee of its 3D Advisory Board. The board was established in the middle of this month.


Dr. Mark McHale has received professional training in genetics, biochemistry and molecular biology at the University of London and the University of East Anglia (UEA UK). From 1986 to 1991, he obtained Ph.D. in molecular biology supervised by Professor Richard Oliver and carried out post-doctoral researches. Currently, he was the Head of R&D, Chief Development Officer and a Founder of ASLAN Pharmaceuticals. He has responsibility for the R&D of novel small molecule and biological therapies for oncology and inflammation, covering preclinical development to phase II clinical trials.


Dr. McHale was once the head of the Department of Pharmaceutical and Molecular Sciences at the Respiratory and Inflammation Division of AstraZeneca Pharmaceuticals, during which he led the department to advance the small molecule and therapeutic antibody project from target recognition to clinical phase II. Dr. McHale has been a core member of the respiratory strategy team of AstraZeneca’s inflammation researches for 5 years, and led the identification and confirmation of all new targets for asthma. He successful helped AstraZeneca start its researches on innate immune system, which can focus on the immune checkpoint modulation mechanism to enhance immune surveillance and avoid anaphylaxis of the immune system. In 2006, he successfully promoted the over USD $136 million investment of the AstraZeneca (AZ) / Dynavax pharmaceutical cooperation project, which aims to prepare inhaled TLR9 agonists for treating asthma. He has also been responsible for a series of development projects that are still in progress and are in clinical phase II.

Before 2001, Dr. McHale spent 7 years at Skipper, where he led the optimization of serotonin and dopamine receptors and was responsible for the optimization project of serotonin and dopamine receptors, and took charge of R&D work of leptin and PPARγ against (Avandia: rosiglitazone). He and Dr. Jackie Hunter worked side by side in the field of neuroscience for three years. Meanwhile, he established a molecular science laboratory and formed a successful team to support molecular analysis of stroke and pain to determine the characteristics of the disease. All the new target discoveries of the team were initiated by GlaxoSmithKline. And a large-scale strategic collaboration laboratory has been established by his team based on human genome science.


Based on its mission - challenge the future with 3D innovation, Great Bay Bio established its 3D Advisory Committee to achieve new breakthroughs in market competitions by combining business forecasts, scientific researches, and technology. At present, it has formed three independent sub-committees (for business, science, and technology), which will lay a solid foundation for the achievement of its mission and realization of the business vision - make global biologics development easier.


With Dr. McHale joining the sub-committee, Mr. Kingsley Leung, Chairman and Co-founder of Great Bay Bio, said: "We are honored to have Dr. McHale join us. Dr. McHale has nearly 30-year experience in pharmaceutical R&D and has worked in Asian and Oceanian countries for more than 10 years. He has abundant experience in different therapeutic areas and knows the R&D culture in different regions, which can promote the diversity and interdisciplinary of our advisory board. When we established the committee, I said that the best innovation comes from cooperation between people with different backgrounds and professional knowledge. Our goal is to cut the high cost of traditional CMC research and make it cheap, which is rather challengeable. Only through reconstruction-based innovation can we realize it. The Dr. McHale’s backgrounds and experience will greatly facilitate the achievement of our mission. I believe that close cooperation with the consultants will provide us with interesting solutions to our problems."



About Great Bay Bio 


Headquartered in Hong Kong, Great Bay Bio (GBB) is a high-tech enterprise developing biologics with AI technologies. Since its foundation, it has been committed to biotech and biologics development. It has founded Dongguan Taili Biotech Co., Ltd. and Guangzhou Taili Biomedical Technology Co., Ltd. Investing more than RMB 300 million, the company has successfully established the independent and integrated technology platform for drug R&D and large-scale preparation. Through customized CMC packaging services, it has successfully helped several products reach NDA stage, some of which are national class I new drugs.

GBB positions itself as a Contract Development and Manufacturing Organization (CDMO), applying AI technology to CMC (Chemistry, Manufacturing, Control) platform for drug development, which targets the drawbacks of drug development including long timeline and high costs, and solves them with the AI+CMC model. Based on massive datum obtained from conventional biologics development, CMC platform can build models and conduct AI analyses. Integrating AI and biotechnology, it can overcome hurdles in biologics development and greatly reduce the time and costs so as to provide much cheaper, efficient and high-quality drug development service for the clients, and also bring much economical drug to the society.

GBB has been recognized as the Patent Incubation Company, Patent Pilot Company, National High-tech Company, Dongguan New Research Institution, Guangdong Top Ten Foreign R&D Center, Guangdong R&D Center of Genetic Engineering Medicine and Engineering, and Guangdong Doctoral Workstation. Since 2006, it has undertaken a number of government projects. More than RMB 20 million has been received from the government to support its provincial and national projects, such as Guangdong-Hong Kong Key Breakthrough Project and National Major New Drug Projects.

The CMC platform has an area of over 3100 m2 and a whole set of advanced biopharmaceutical R&D equipment. The key equipment has been purchased from world-renowned manufacturers such as Sartorius, Bio-Rad, GE Healthcare, and Waters. The pilot workshop is designed strictly in accordance with cGMP requirements, mainly at the C level and some even at the A level.



For more details, please visit:www.greatbay-bio.com

Contact for business:js.chen@greatbay-bio.com

Contact for media and investment: public@greatbay-bio.com

Home    News    A New Member Joins the Science Sub-Committee of Great Bay Bio’s 3D Advisory Board